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Abstract: Lymphomas are heterogeneous diseases, and the term includes a number of histological
subtypes that are characterized by different clinical behavior and molecular phenotypes. Valuable
information on the presence of lymphoma cell-derived extracellular vesicles (LCEVs) in the
bloodstream of patients suffering from this hematological cancer has recently been provided.
In particular, it has been reported that the number and phenotype of LCEVs can both change
as the disease progresses, as well as after treatment. Moreover, the role that LCEVs play in driving
tumor immune escape has been reported. This makes LCEVs potential novel clinical tools for
diagnosis, disease progression, and chemoresistance. LCEVs express surface markers and convey
specific molecules in accordance with their cell of origin, which can be used as targets and thus lead
to the development of specific therapeutics. This may be particularly relevant since circulating
LCEVs are known to save lymphoma cells from anti-cluster of differentiation (CD)20-induced
complement-dependent cytotoxicity. Therefore, effort should be directed toward investigating
the feasibility of using LCEVs as predictive biomarkers of disease progression and/or response
to treatment that can be translated to clinical use. The use of liquid biopsies in combination with
serum EV quantification and cargo analysis have been also considered as potential approaches that
can be pursued in the future. Upcoming research will also focus on the identification of specific
molecular targets in order to generate vaccines and/or antibodies against LCEVs. Finally, the removal
of circulating LCEVs has been proposed as a simple and non-invasive treatment approach. We herein
provide an overview of the role of LCEVs in lymphoma diagnosis, immune tolerance, and drug
resistance. In addition, alternative protocols that utilize LCEVs as therapeutic targets are discussed.
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1. Introduction
Lymphomas are a group of hematopoietic-derived cancers that develop from lymphocytes.
The name specifically refers to the cancerous subtypes rather than to a single disease. Several lymphoma
subtypes are recognized and belong to two main groups: Hodgkin lymphoma (HL), and non-Hodgkin
lymphoma (NHL). HL is a rare malignancy, with an incidence of about 2.4 per 100,000 per year, and is
divided into nodular lymphocyte-predominant HL (5%) and classical HL (95%). Nodular lymphocyte
HL is further subdivided into nodular lymphocyte-predominant HL, nodular sclerosis classical HL,
mixed cellularity classical HL, lymphocyte-rich classical HL, and lymphocyte-depleted classical HL [1].
NHL counts for 90% of all lymphomas [2]. Common NHLs affect children, adolescents, and young
adults of up to 30 years of age (CAYA). NHLs in the CAYA population include lymphoblastic diseases
such as acute lymphoblastic leukemia/lymphoma and ALL/LL, which originate from immature B or
T cells, and Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and anaplastic large cell
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lymphoma (ALCL), which originate from mature peripheral lymphocytes [3]. The most frequent NHLs
are follicular lymphomas (FL) and DLBCL (70%). The histological transformation of FL to aggressive
lymphoma occurs in 35% of patients and is associated with poor outcomes [4].
Six defined hallmarks allow cells to survive, proliferate, and disseminate in hematologic cancers,
just as in solid tumors. These include: (1) sustained proliferative signals, (2) growth suppressor
evasion, (3) replicative immortality, (4) invasion, (5) angiogenesis, and (6) resistance to cell death [5].
The acquisition of such features depends on the development of cancer cell genomic instability, immune
system-driven inflammation, the reprogramming of tumor cellular energy metabolism, and tumor
evasion from immune surveillance [5].
Growing amounts of evidence point to extracellular vesicles (EVs) functioning as pivotal
mediators of cell–cell communication among both neighboring and distant cells in physiological
and pathological settings, including hematological malignancies [6,7]. EV-specific deoxyribonucleic
acids (DNA), lipids, distinct ribonucleic acids (RNA) repertoires, and proteins have been observed
to change in response to different circumstances [8]. More importantly, EV cargoes profoundly
differ in untransformed and transformed cells [9]. Moreover, EVs contribute to the signaling
networks in the tumor microenvironment (TME) and promote tumor progression, immune escape,
and chemoresistance [10]. Finally, EV cargo and their surface markers, which are parent-cell specific,
are known to provide insight into tumor identity, making them valuable surrogate biomarkers [11].
Relevant data on the role of lymphoma cell-derived extracellular vesicles (LCEVs) in lymphoma
diagnosis, immune escape, and chemoresistance will be discussed in this review. Moreover, an update
on the exploitation of LCEVs as therapeutic targets will be provided.
2. EV Biogenesis
Exosomes and microvesicles are highly heterogeneous particles that originate from distinct
subcellular compartments. They present a range of sizes and have diverse molecular composition.
They have been classified into three main groups: (1) microvesicles (MVs), which are also referred to
as ectosomes, shedding vesicles, or microparticles, and are formed by the outward budding of plasma
membranes and present diameters ranging from 100 to 1000 nm; (2) exosomes, which are formed
inside multivesicular bodies (MVBs) via the intraluminal budding of the endosomal membrane and
are smaller than MVs, with diameters ranging from 30 to 100 nm; (3) apoptotic bodies (ABs) are large
clumps of material (1000–5000 nm) that originate from cells undergoing apoptosis [12,13]. MVs and
exosomes have recently been collectively defined as extracellular vesicles (EVs) [14], and this term will
be used throughout this review to describe both MVs and exosomes.
EVs are important mediators of cell-cell communication that play key roles in both normal and
disease processes, including cancer development and progression [15,16]. EVs contain cell-type specific
cargo, including RNAs, DNA, and proteins, which are selectively sorted [17].
The mechanisms that are involved in EV biogenesis are not yet fully clear. However, it is
generally accepted that the endosomal sorting complex required for transport (ESCRT)-dependent and
ESCRT-independent signals play a crucial role in this process [17]. Once released, EVs induce a variety
of signals to recipient cells [18]. After release, EVs are taken up by target cells. The mechanisms
for EV uptake mainly include direct membrane fusion [19], ligand-receptor interactions [20],
and phagocytosis [21], as well as clathrin-dependent [22] and clathrin-independent [23] endocytosis.
EVs then release their cargo into recipient cells and induce a number of biological functions [24].
EV composition closely reflects their biogenesis and the environmental conditions of the cell of
origin, and includes portions of cytosol and membrane-associated materials [25]. EV membranes
are enriched in gangliosides and transferrin receptors [26], as well as cholesterol, ceramide,
and sphingomyelin [27]. Furthermore, they contain several endosome-specific proteins, including
cluster of differentiation (CD)9, CD63, CD81, tumor susceptibility 101 (Tsg101), and ALG-2-interacting
protein X (Alix). EV release depends on calcium influx, cytoskeleton reorganization, and the
redistribution of phospholipids in the plasma membrane [28,29].
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EV composition in the physiological setting largely depends on the cell type from which they
originate. They transfer information and induce the reprograming of target cells in a specific
manner [30,31]. EVs transport non-coding RNA species, including RNA transcripts that overlap
with protein coding regions, repeat sequences, structural RNA, transference RNA (tRNA) fragments,
vault RNA, small non-coding RNA (Y RNA), and small interfering RNA, as well as other small
molecules [32,33]. Besides RNAs, the presence of nucleic acids, such as mitochondrial DNA
(mtDNA) [34], single-stranded DNA (ssDNA) [35], and genomic double-stranded DNA (dsDNA) [36]
has been described. Although the mechanism involved in EV DNA trafficking is not clear, the transfer
of packaged genomic sequences that are released into the cytoplasm after nuclear-envelope breakdown
during mitosis has been postulated [37].
3. LCEVs and LME
The molecular content of tumor-derived EVs includes a broad variety of proteins, lipids, glycans,
and RNA species, and partly resembles the content of their parental cell (Figure 1) [38,39]. Furthermore,
tumor-derived EVs may contain immunoinhibitory ligands and immunostimulatory molecules [40,41].
Malignant transformation is associated with increased EV release [38,42,43]. Moreover, cancer and
lymphoma cells produce a large number of EVs that also contain molecules, driving the apoptosis
of activated tumor-specific T cells, and thus impairing their cytolytic activity [38,39,44]. Overall,
tumor-derived EVs differ from “healthy” cell-derived EVs in their functional and structural properties,
as well as in their molecular profile [38,45]. Indeed, their phenotype depends on the stage and grade
of malignancy [38,46]. There are increasing amounts of evidence to indicate that tumor-derived EVs
preferentially target tumor cells rather than cells that are contained in normal tissues [47]. However,
the precise mechanisms of interaction and affinity between tumor-derived EVs and target cells are still
a matter of study.
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Figure 1. Lymphoma cell-derived extracellular vesicle (LCEV) cargo. LCEVs may contain nucleic
acids, proteins, and lipids that resemble the content of their parental cell. The LCEV surface membrane
is enriched with proteins that are involved in antigen presentation, signal transduction, adhesion,
and drug resistance. Major histocompatibility complex (MHC) class I and II (MHC I/II); miRNA:
micro-ribonucleic acid; ABCA3: ATP-binding cassette transporter A3; ICAM-1: Intercellular Adhesion
Molecule 1; ADAM10: A Disintegrin and Metalloproteinase Domain-containing protein 10; HSP 70/90:
Heat shock protein 70 and 90. Wnt3a: Wingless 3a. Red arrows indicate up-regulated molecules.
The p esence of genomic DNA inside tumor c ll-der ved EVs as been also reporte [48].
The majority of DNA is d uble-stranded genomic DNA, resembling that of the cell of origin,
and includes mutated and amplified oncogenes as well as transposable elements [35,36,38] (Figure 1).
The function of this EV-DNA cargo is still unclear.
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The importance of EVs in hematological malignancies is, in part, attributed to their role in driving
the hypercoagulability state, changing the tumor microenvironment and inducing tumor evasion and
chemoresistance [49].
The lymphoma microenvironment (LME) participates in lymphoma by promoting tumor cell
proliferation, resistance to cell death, and evasion from growth suppressors, and provides immune
escape mechanisms [4]. The LME has been increasingly recognized as a dynamic and interactive system
that also supports and guides drug resistance [4]. Key factors that influence LME composition include
lymphoma subtypes and signaling interactions between lymphoma cells and the cells contained within
the LME. A deeper knowledge of the interaction between lymphoma cells and their non-malignant
microenvironment is thought to be critical to the identification of the mechanisms involved in
lymphoma initiation/development and new therapeutic targets [50].
The LME consists of immune cells, stromal cells, cytokines, blood vessels, and extracellular matrix
components, just as the TME. Moreover, EVs have more recently been considered to be relevant LME
components [39] (Figure 2). LME composition (Table 1) is dynamic and mainly guided by cancer cells.
Moreover, a bidirectional flux of information between LCEVs and EVs that are derived from LME
components has been reported to influence LME composition and tumor cell features [51]. Indeed,
Hansen et al. [52] have demonstrated that LCEVs that are enriched in CD30 are released into the LME
and take part in the recruitment of microenvironment resident cells. More recently, it has also been
reported that lymphoma B cell-derived EVs that contain mutated Myeloid differentiation primary
response 88 (MYD88) are involved in bone marrow LME reprogramming [53].
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Figure 2. Cellular interaction in the lymphoma microenvironment (LME) driving immune escape.
LCEVs contribute to tumor immune escape by coordinating the activation (black arrows) and/or
inactivation (T bars) of different cells types in the tumor niche. LCEVs express different surface
markers (cluster of differentiation: CD) and transport typical components resembling their c ll of origin
(lymphoma cell). Key molecules enriched in LCEVs interact with receptors expressed by target cells and
activate intracellular signals that differentially modulate the activity of immune cells. The activation of
DCs and fibroblasts further promote EV release and EV-mediated signaling events in neighboring cells.
DC: Dendritic cells; NK: Natural killer cells.
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Table 1. Lymphoma Microenvironment (LME) composition.
LME-Associated Composition Cell Types
Immune cells
Cytotoxic T cells (CTLs)
Follicular B helper T cells (TFH)
Regulatory T cells (Treg)
Natural Killer cells (NK)
Bystander B cells
Stromal cells
Mesenchymal stromal cells (MSCs)
Lymphoma associated macrophages (LAMs)
Myeloid-derived suppressor cells (MDSCs)
Dendritic cells
Extracellular components
Extracellular matrix (ECM)
Cytokines/Chemokines
Lymphoma exosome
4. Immune Regulation by Tumor-Derived EVs
The immune response is made up of innate and adaptive immunity. The innate response depends
on antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), and natural killer
cells (NK). The adaptive response relies on specific B and T lymphocyte activation and the generation
of memory T cells. T cells are highly specialized cells that not only coordinate (T-helper: Th) and
suppress (T-regulatory: Treg) the immune response, but also destroy infected cells (T-cytotoxic: CTL).
Furthermore, B cells secrete antibodies that mark infected cells and pathogens in order to promote
their removal from circulation [54,55].
Tumor cells, besides being characterized by unrestrained cell proliferation, possess powerful
defensive mechanisms that allow them to escape immune surveillance and confer them with
chemoresistance. Although EVs can display stimulatory or tolerogenic properties, depending on
their packaged cargo, tumor-derived EVs mainly induce cues that collectively suppress the immune
attack against tumors [56]. However, it has been shown that tumor-derived EVs are able to transfer
tumor antigens to DCs by means of their major histocompatibility complex (MHC) class I expression,
which, in turn, induces a CD8+ T cell-dependent antitumor immune response [57]. In order to escape
immune surveillance and prepare a “niche” for newly generated and dispersed tumor cells, two main
strategies are generally adopted by tumor cells: (1) the production of immune suppressive cytokines,
and (2) the loss of target antigens to avoid their recognition by immune cells [58]. As a matter of fact,
tumor-derived EVs deliver surface signals that modulate the expression of immunoregulatory genes,
such as cyclooxygenase 2 (COX2), interleukin (IL)-10, CD39, CD73, programmed death-ligand (PDL)-1,
and CD26, which suppress regulatory T cells (Treg cells) [59]. Additionally, tumor-derived EVs can
promote the production of prostaglandin E2 (PGE2), IL-6, and tumor growth factor β (TGF-β) from
myeloid-derived suppressor cells (MDSC) [60]. CD8+ and CD4+ T lymphocytes are also differentially
modulated by circulating tumor-derived EVs. In fact, while they inhibit CD8+ activation and
proliferation, they have no effect on CD4+ T cells. Additionally, tumor-derived EVs induce apoptosis
in CD8+ T cells and enhance CD4+T regulatory cell suppressor activity [61]. EV immunoregulatory
effects are not limited to T and B cells, but also involve NK cells. In fact, tumor-derived EVs are
known to repress NK activity via a mechanism that involves the interaction of the MHC class I-related
chain (MIC) with the natural killer group 2D receptor (NKG2D) [62]. In particular, tumor-derived
EVs considerably reduce the cytotoxic activity of circulating NK and generate an immunoprivileged
environment that facilitates tumor escape by downregulating NKG2D [63].
Therefore, tumor-derived EVs use the above strategies to potentiate the immunosuppressive
microenvironment and favor tumor growth by: (1) reprograming macrophages toward a M2
tumor-supportive phenotype [64,65]; (2) inducing cytotoxic CD8+ T cell apoptosis [64], thus lowering
NK proliferation; and (3) shifting CD4+ cells to T regulatory lymphocytes [66].
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5. EV-Mediated Lymphoma Immune Escape
Immune cells have distinct roles in lymphoma progression. They induce both immunosuppressive
and antitumor immune responses. Lymphoma cells play an important role in directing tumor
immune escape by creating a feasible tumor microenvironment. A number of strategies are adopted
by the cells to obtain this goal: (1) the direct recruitment of immune cells [67]; (2) the indirect
“education” of normal cells to release a specific pattern of cytokines or chemokines [68–70]; and (3)
the reprogramming of resident fibroblasts to cancer-associated fibroblasts (CAF) [71]. It is known
that Treg cells exert immune-suppressive activity on lymphoma-infiltrating cytotoxic T cells, resulting
in ineffective immune clearance [72]. This mechanism is secondary to the recruitment, proliferation,
and differentiation of naive CD4+ T cells, which is induced by chemokines and the growth factors that
are secreted by the cells and/or by the LME components [4].
The study of tumor-derived EVs and their role in disease progression is currently one of the
most attractive topics across cancer research, including that on lymphomas [39]. Despite the amount
of data generated in recent years, further effort is still required if a detailed characterization of
the structural and functional diversity of LCEVs and their role in immune escape mechanisms
is to be achieved. LCEVs transport more than 70% of the proteins derived from their parental
cells [40]. As a matter of fact, LCEVs contain discrete sets of proteins that are involved in antigen
presentation, signal transduction, and cell adhesion. LCEVs also carry tumor antigens and MHC I,
and are loaded with tumor surface molecules, such as CD19, CD20, and CD22, which may participate
in the important signaling pathways that are involved in cell-to-cell communication in LME [40]
(Figure 3). Higuchi et al. [73] have demonstrated that Epstein-Barr virus (EBV)-associated lymphomas
secrete LCEVs that are mainly incorporated into monocytes/macrophages and support tumor evasion
by inducing the immune regulatory phenotype in macrophages. Additionally, Ahmed et al. [74]
have demonstrated that EBV infection in B cells may induce T-cell depression via LCEV-mediated
apoptosis. Immune and non-immune mechanisms have been described [74]. LCEV-dependent
cell-to-cell communication between distant lymphoma cells also involves educational mechanisms
that are driven by CD30+ LCEVs. This mainly includes bidirectional cross-talk between malignant
cells and resident fibroblasts [71]. Recent data have demonstrated that HL cells release LCEVs that
express the full-length CD30 receptor and can locally modify the LME via interactions between their
ligands (CD30L+) and neighboring cells. Moreover, bidirectional CD30-CD30L+ signals have been
reported to contribute to the education of distant immune cells [52].
NK cells, and in particular their germline-encoded receptor NKG2D, have also been shown to play
a role in NK-mediated immunosurveillance in lymphoma [75]. NKG2D is an activating molecule that
recognizes self-molecules that are induced by stress [76]. Cancer cells overexpress NKG2D, and this
translates into the upregulation of its ligands and more efficient NKG2D-dependent NK-mediated
cell killing [77,78]. However, it has been reported that the downregulation of NKG2D-L is a common
feature in LME, and is a relevant tumor-escape mechanism, as it suppresses NKG2D-dependent
cytotoxicity [78]. Moreover, LCEVs that are enriched in NKG2D ligands also contribute to immune
escape by decreasing the number of NKG2D-positive T cells [79].
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Interference with T cell homing that prevents the systemic antitumor immune response has been
associated with the overexpressio of endothelin B on tumor endothelial cells in solid tumors [80].
Further studies should be performed to investigate the possibility that such a mechanism is also
present in LME.
6. LCEVs and Angiogenesis
Increased angiogenesis has been detected in the bone marrow of patients with hematologic
disorders, including lymphomas [81]. Angiogenesis is required for tumor development, growth,
and invasion. The process is regulated directly and indirectly by malignant cells using a variety of
pro-angiogenic and anti-angiogenic mediators, including: (1) miRNAs; (2) proteins; (3) lipids; and (4)
transcription factors [82].
Tumor-derived EVs also promote angiogenesis by inducing stroma cells to release several
pro-angiopoietic factors [83]. More recently, it has been shown that tumor-derived endothelial cells
directly act on neighboring cells via EV-mediated miRNA transfer [84]. LCEVs that express Heat
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Shock Protein 70 kilodaltons (HSP-70), myelocytomatosis cancergene (c-Myc), B-cell lymphoma 2
(Bcl-2), myeloid cell leukemia sequence 1 (Mcl-1), X-linked inhibitor of apoptosis protein (xIAP),
B-cell lymphoma-extra-large (Bcl-xL), and other molecules, such as phosphatidylinositol, Extracellular
signal-Regulated Kinases (ERK), Mitogen-Activated Protein Kinases (MAPK), chemokines, cell surface
receptors, and G proteins also act on angiogenesis [85]. Indeed, LCEVs that are released in LME
actively participate in the angiogenic processes by delivering mRNA, miRNAs, and angiogenic
proteins, including Vascular Endothelial Growth Factor (VEGF) [86].
7. Liquid Biopsy as a New EV-Based Screening Method
Solid biopsy is the gold standard for the diagnosis of a variety of diseases, particularly cancers.
However, tumors that cannot be surgically treated and/or present limited accessibility are a major
limitation of solid biopsies. Liquid biopsies have recently been proposed as a means to supplement
surgical biopsy and resolve its limitations [87].
A “liquid biopsy” is a minimally invasive blood test that provides a consistent non-invasive
clinical tool for the molecular profiling of cancer patients [87]. This approach may allow tumor cells,
tumor DNA, miRNAs, and tumor-derived EVs to be identified in circulation. Moreover, liquid biopsies
are currently being used to obtain more accurate diagnoses, identify specific biomarkers, and monitor
disease progression, clonal evolution, and the response to treatment [88]. Accordingly, liquid biopsies
have been proposed as an alternative diagnostic method for the screening of new biomarkers in LCEVs
that may be translated to the clinic.
8. LCEVs as Markers of Disease and Progression
HL and NHL cells express more than 1000 membrane proteins, including 178 protein clusters.
HL and NHL specific markers have been proposed as new molecular candidates for differential
diagnosis between HL and NHLs [89]. HL cell lines and tumor tissues from HL patients express a
number of proteins that are involved in immune response. Additionally, the enrichment of activated
leukocyte cell adhesion molecule (ALCAM), cathepsin S, CD26, CD44, interleukin 1 receptor 2 (IL1R2),
macrophage migration inhibitory factor (MIF), and thymus and activation regulated chemokine (TARC)
in the plasma of HL patients has been correlated with lymphoma progression [90]. CD81+ and CD63+
LCEVs are particularly enriched in CD19, CD20, CD24, CD37, and HLA-DR [91]. The number of
specific LCEVs and their surface markers also correlate with lymphoma subtypes. For example,
LCEVs isolated from NHL patients are enriched in CD19 and CD20, while EVs isolated from patients
with HL are enriched in CD30 [92]. In particular, CD20+ LCEVs are considered the best biomarkers
for disease progression and antibody-based treatment response, as their circulating level directly
correlates to the CD20+ circulating cells in patients [93]. Sera from HL patients also contain a high
number of CD30+ LCEVs [92], which has been correlated with patient outcomes [94]. Therefore,
CD30+ LCEVs, besides representing a valuable diagnostic marker, might also be used to monitor
responses to treatment [95]. Likewise, Tosetti et al. [96] have demonstrated that LCEVs released by
HL cells are enriched in the mature bioactive form of ADAM10. In addition, Jones et al. [97] have
demonstrated that miRNA-21 and miRNA-155 are enriched in the sera of HL patients. Accordingly,
a standardized size-exclusion chromatography (SEC) analysis has demonstrated the presence of more
than 400 miRNAs in the highly enriched populations of HL patient-derived LCEVs. miRNA-21,
miRNA-155, miRNA-21-5p, miRNA-24-3p, miRNA-127-3p, and let7a-5 are found among them [97].
A large Spanish multicentric study has recently demonstrated the feasibility of monitoring cancer
evolution by measuring B-cell lymphoma 6 (BCL-6) and C-MYC mRNA levels in LCEVs isolated
from the plasma of patients with B-cell lymphomas. The study also demonstrated that both markers
are predictors of worse progression-free survival (PFS). Moreover, it has been shown that LCEV
C-MYC mRNA content may also predict poor prognosis and/or incomplete treatment response [98].
The relevance of LCEVs as potential predictors of drug efficacy has also been demonstrated in patients
with diffuse DLBCL. The observation that two miRNAs (miRNA-99a-5p and miRNA-125b-5p) were
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enriched in DLBCL EVs was found to correlate with shorter progression-free survival and drug
resistance [99]. Finally, a direct correlation between circulating LCEV number, disease progression,
and response to treatment has been reported [38]. These observations support the notion that LCEVs
can be considered not only as potential markers of disease and disease progression, but also as
biomarkers to monitor response to treatment.
9. LCEVs as Mediators of Drug Resistance
The identification of a suitable B-cell target antigen, CD20, in the early 1980s paved the way for
the development of monoclonal antibody technology, and in particular promoted an immunological
therapeutic approach to NHL patient treatment [100]. CD20 is a membrane-spanning phosphoprotein
that is expressed by late pre-B and mature B cells, as well as by the majority of NHL B cells. The absence
of this marker on early B-cell progenitors and immature cells facilitated the development of a specific
antibody-based therapy that can recognize human CD20 and induce complement-dependent (CDC)
and antibody-dependent cellular cytotoxicity (ADCC) [101]. Rituximab was the first anti-cancer
biological drug to be approved as an anti-CD20 antibody (RTX; Rituxan®, MabThera®) by the United
States (US) Food and Drug Administration in 1997 [102].
The last decade has seen a new anti-CD20-based therapy for lymphoma treatment being developed
and approved [103]. Unfortunately, it is becoming evident that B-cell lymphoma cells release CD20+
LCEVs. It has been suggested that circulating CD20+ LCEVs capture rituximab, and thus hamper its
therapeutic effect. This seems to be particularly relevant at the beginning of treatment. In particular,
it has been demonstrated that the high number of circulating CD20+ LCEVs can “sequestrate”
rituximab, reducing the effective number of deposable molecules, and in turn, reducing its therapeutic
effectiveness [104]. Moreover, it has been reported that LCEVs efficiently extrude drugs and can drive
drug resistance in aggressive B-cell lymphomas via the ATP-transporter A3-mediated mechanism
(ABCA3) [105]. The expression of HSP-70, c-Myc, Bcl-2, Mcl-1, xIAP, and Bcl-xL and other molecules,
such as phosphatidylinositol, ERK, MAPK, chemokines, cell surface receptors, and G proteins in LCEVs
has also been associated with resistance against humoral immunotherapy [85]. Moreover, the increase
in ADAM10 activity that is mediated by LCEVs has been reported to interfere with immunotherapeutic
approaches. The release of Tumor Necrosis Factor (TNF)α, soluble MHC I polypeptide-related sequence
A (sMICA), and soluble CD30 (sCD30) has been reported as a crucial mechanism [96]. This observation
has led to specific ADAM10 blockers being proposed to boost the anti-lymphoma immune response
and/or drive efficient antibody-drug-conjugate (ADC)-based and Ab immunotherapy [96].
10. EV-Based Lymphoma Therapies
Tumor-derived EVs are involved in cancer development on multiple levels. It is worth noting
that EVs also drive “adaptation/defense” and chemoresistance mechanisms [106]. This has spurred
current research toward feasible approaches that can interfere with the formation/release or spread
of tumor-derived EVs. Researchers are currently focusing on four main areas: (1) EV-based vaccines;
(2) the development of specific antibodies to neutralize tumor-derived EVs; (3) the targeting of EV
biogenesis; and (4) the extracorporeal removal of tumor-derived EVs (Figure 4).
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using LCEVs. Oncogenic drugs and specific antibodies targeting surface molecules expressed by LME
components represent the main therapeutic approaches used in clinic. Current clinical trials are also
evaluating new potential approaches using vaccinations with tumor antigens. ADAPT represents
a potential approach to remove LCEVs from the bloodstream. Liquid biopsy has been proposed as
screening method for diagnosis, disease progress, and response to therapy. New potential approaches
are represented by the chimeric antigen receptor (CAR), which is introduced in immune cells to retarget
their cytotoxicity toward specific tumor antigens (CART). CARs are synthetic proteins generated
by the fusion of a single chain variable fragment (scFv) derived from a monoclonal antibody with
the signaling and costimulatory machinery of the T-cell receptor (TCR) [107]. CART cells have been
evaluated as promising new cell-based therapy approach using CD19 [108], CD30, CD123 [109],
and the Epstein-Barr virus protein (EBV) as molecular targets [110]. ADAPT: daptive dynamic
artificial poly-ligand targeting.
10.1. EV-Based Vaccines
Cancer vaccines are considered a class of therapeutics and are also called biologic response
odifiers (BR ) [111]. Single or combined tumor antigens are injected to drive immunoprotection [112].
The identification of selective antigens that are abundantly expressed on cancer cells has set the basis
for the design of a number of cancer vaccine trials [113]. However, there are few data to demonstrate
the feasibility of monitoring the immune response, meaning that vaccination is not yet considered a
feasible therapeutic approach for lymphoma [114].
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The heterogeneity of the molecular profile of tumor cells during progression and after treatment is
considered the most relevant limitation of vaccination-based cancer therapy. Moreover, antigen-specific
T-cell repertoire diversities, and the presence or absence of pre-existing immune tolerance, have also
contributed to unsuccessful responses to vaccine-based therapy [115].
It has been reported that HL-derived LCEVs are able to induce a potent and specific cytotoxic
response in CD8+ T lymphocytes. This effect relies on the upregulation of MHC molecules,
costimulatory molecules, and cytokines by LCEV-mediated DC functional maturation [85]. DCs,
which are the most proficient APCs, can take up tumor antigens and, depending on environmental
cues, present antigens at tumor sites and lymphoid organs to either prime, sustain, or abrogate
EV-based active vaccination [116]. Menay et al. [117] have demonstrated that T-cell lymphoma-derived
LCEVs are able to induce an efficient immune response and memory against lymphoma. This effect
was associated with T helper 1-mediated responses. However, Chen et al. [85] have more recently
demonstrated the presence of a dual LCEV-mediated effect. They showed that LCEVs may display
immunosuppressive activity that can promote in vivo tumor growth. On the other hand, they also
demonstrated that T cells, which were recovered from tumor-bearing mice treated with LCEVs,
displayed increased anti-lymphoma activity. This effect relies on DC-mediated T-cell expansion and
the inhibition of Th2 immunosuppressive activity [85]. These data suggest that the education of DCs
using LCEVs as tumor-associated antigens may be a novel DC-based immunotherapy [85].
More recently, the combined use of standard-of-care chemotherapeutics and EV-based vaccines has
been proposed as a means to modulate immunity in solid tumors. For example, cyclophosphamide has
been shown to amplify the cytotoxic T-cell response against cancers when combined with DC-derived
EVs [118,119]. Future effort should be devoted to an evaluation of the effectiveness of this combined
approach as an alternative treatment in lymphomas as well.
10.2. Neutralizing EV-Based Approaches
Although rituximab has been shown to improve the overall survival of patients with both
aggressive and indolent B-cell NHL [120], remission is only achieved in 50% of CD20-positive
lymphoma patients [120]. This indicates that additional and more specific antibodies are
required. CD19, CD22, CD37, and CD40 have been identified, thanks to lymphoma molecular
profiling [89], and are currently under investigation for the development of new antibody-based
treatments. A number of new specific antibodies, including the anti-CD22 [121], anti-CD40 [122],
anti-CD19 [123], anti-CD19/CD3 [124], and anti-CD37 antibodies [125], are currently used for
alternative antibody-based therapy in lymphomas. Since these markers [40] are also expressed by
LCEVs, these approaches, if validated, could also be used to remove LCEVs from circulation. Therefore,
a dual effect may be sought.
10.3. Targeting EV Biogenesis
The blockade of EV release from tumor cells has been proposed as an alternative EV-mediated
therapeutic approach in cancer [126]. The identification of key cellular pathways that are involved in EV
biogenesis would be crucial to this purpose. It has been demonstrated that EBV infection modulates EV
biogenesis and the miRNA content in Burkit lymphoma cells [127]. However, the complex biological
process of EV trafficking and the large number of proteins involved represent a significant challenge.
Despite the enormous amount of effort that has been made to identify the signaling pathways
involved in LCEV formation and release, few data are currently available. Koch et al. [105] have
recently shown that LCEV biogenesis is strictly dependent on ATP Binding Cassette Subfamily A
Member 3 (ABCA3) expression, and that genetic ablation and chemical interference with ABCA3
expression improve drug accumulation in the nucleus of B-cell lymphomas.
The inhibition of sphingolipid ceramide formation via a range of approaches has also been shown
to interfere with intra-endosomal membrane transport and EV generation [17,128]. Several imidazoles
(neticonazole, ketoconazole, and climbazole) as well as manumycin A20 (MA) and tipifarnib, which are
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two farnesyl transferase inhibitors (FTIs), have been found to inhibit the specific pathways that are
involved in EV biogenesis in cancer cells [129].
The Rab family is known to control vesicular trafficking, including its motility, docking, budding,
and the fusion of numerous vesicular transport intermediates [130]. More importantly, the enrichment
of Rab35 on EVs has been shown to play a crucial role in the regulation of vesicle density [131].
Ostrowsky et al. [132] have demonstrated that several Rab family members are also involved in EV
biogenesis and provide noticeable results, which strengthens the concept of using Rab27 inhibitors to
interfere with EV biogenesis.
The role of intracellular Ca2+ concentration has also been reported to contribute to EV biogenesis
in erythroleukemia cell lines. This was observed using dimethyl amiloride (DMA), which is an inhibitor
of Na+/H+ and Na+/Ca2+ exchangers. In particular, it has been shown that DMA is able to decrease
constitutive and Ca2+-dependent EV release [133]. DMA was also found to reduce the secretion of
LCEVs in mice that bear lymphomas. This translates into the inhibition of myeloid-cell suppressor
functions and an improvement in immune surveillance [134].
10.4. Extracorporeal Removal of LCEVs
EV dialysis has been proposed as a novel approach for the removal of EVs in cancer and lymphoma
patients [135]. However, no solid data on EV removal by hemofiltration are yet available. Nevertheless,
Aethlon Medical has proposed a therapeutic hemofiltration approach, termed the Aethlon ADAPTTM
(adaptive dialysis-like affinity platform technology) system, which consists of immobilized affinity
agents in the outer-capillary space of hollow-fiber plasma separator cartridges integrated with either a
standard dialysis unit or with devices approved for continuous renal replacement therapy (CRRT) [135].
So far, the combination of this technology with dialysis has been applied to virus reduction/clearance
in hepatitis C-infected patients. Feasibility was indirectly supported by a reduction in the number
of infected cells [135]. Therefore, its potential application in LCEV removal still requires validation,
despite this approach being a valuable innovative option.
11. Conclusions
EVs have been increasingly considered simple and accurate non-invasive biomarkers in many
cancers [11]. In particular, LCEVs have been investigated as novel “multiomic shells” for disease
detection, immune escape, response to treatment, and drug resistance. Moreover, the cross-talk that
occurs between malignant cells, immune cells, and other LME components via LCEVs has gained
particular attention for its role as a driver of lymphoma progression and treatment response [6].
Recently, it has been reported that circulating EVs that bear programmed death-ligand 1 (PD-L1)
change during treatment, due to specific immune responses [136]. This suggests that LCEVs could be
used as real-time biomarkers for treatment response [137]. Moreover, the use of LCEVs as biomarkers
of treatment response would be particularly relevant for patient management during treatment,
as the International Prognostic Index (IPI) predicts survival time, but not treatment efficacy [138].
Furthermore, most lymphoma-associated antigens being expressed on LCEVs has led to the proposal
of the possibility of using them for immune approaches [38]. This is further supported by the finding
that LCEVs carry a large number of proteins that can be considered potential target candidates [40].
Effort has also been focused on the identification of the mechanisms that regulate LCEV biogenesis.
This would allow the development of novel therapeutic approaches in which the targeting of LCEVs
might interfere with tumor growth. This would also be particularly relevant if interfering agents could
be directed to CD20+ LCEVs, which are known to act as decoy targets to facilitate tumor escape from
humoral immunotherapy [139]. However, a refined and detailed understanding of LCEV actions is
still required if advanced therapeutic options are to be successfully developed. Moreover, an in-depth
investigation of the relationship between LCEVs, disease aggressiveness, and recurrence would also
provide assistance. These topics must be addressed before the LCEV field can be translated to the clinic.
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